Ticker Details
MannKind Corporation MannKind Corp is engaged in the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and cancer. Its products and technologies include Afrezza, Dry powder formulation, Inhalation profiling, and others.
IPO Date:	July 28, 2004
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.33B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.18 | 3.49%
Avg Daily Range (30 D):	$0.11 | 2.66%
Avg Daily Range (90 D):	$0.11 | 3.03%

Institutional Daily Volume
Avg Daily Volume:	2.9M
Avg Daily Volume (30 D):	3.99M
Avg Daily Volume (90 D):	4.42M

Trade Size
Avg Trade Size (Sh.):	304
Avg Trade Size (Sh.) (30 D):	197
Avg Trade Size (Sh.) (90 D):	219

Institutional Trades
Total Institutional Trades:	4,041
Avg Institutional Trade:	$1.61M
Avg Institutional Trade (30 D):	$1.76M
Avg Institutional Trade (90 D):	$2.44M
Avg Institutional Trade Volume:	.26M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.94M
Avg Closing Trade (30 D):	$2.16M
Avg Closing Trade (90 D):	$2.87M
Avg Closing Volume:	400.43K

News

Jun 5, 2026 @ 11:35 PM Data at ADA 2026 Highlights Key Findings from Clin... Source: Mannkind Corporation

May 29, 2026 @ 6:00 PM MannKind to Host Conference Call Today to Discuss ... Source: Na

May 27, 2026 @ 8:00 PM MannKind to Present at Jefferies Global Healthcare... Source: Na

May 12, 2026 @ 2:30 PM The $59B Quiet Shift Reshaping How Patients Access... Source: Equity Insider

Mar 18, 2026 @ 2:00 PM A Key "Master" Protein That Declines by Half After... Source: Equity-Insider.Com

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-.13	$-.06	$-.05
Diluted EPS	$-.13	$-.06	$-.05
Revenue	$393.63M	$109.37M	$90.17M
Gross Profit	$353.29M	$94.97M	$82.66M
Net Income / Loss	$-43.61M	$-19.03M	$-16.62M
Operating Income / Loss	$9.19M	$-.35M	$-1.67M
Cost of Revenue	$40.34M	$14.41M	$7.51M
Net Cash Flow	$-4.07M	$.1M	$-22.05M
PE Ratio

Splits
Mar 03, 2017	1:5